A5043268917- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Chronic Myeloid Leukemia Treatments
- SARS-CoV-2 and COVID-19 Research
- Multiple Myeloma Research and Treatments
- Biosimilars and Bioanalytical Methods
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- COVID-19 Clinical Research Studies
- Systemic Sclerosis and Related Diseases
- Clinical Nutrition and Gastroenterology
- Cancer Treatment and Pharmacology
- Integrated Circuits and Semiconductor Failure Analysis
- Renal Transplantation Outcomes and Treatments
- T-cell and B-cell Immunology
Institut Gustave Roussy
2016-2025
Hospital General Universitario Morales Meseguer
2009-2024
Université Paris-Saclay
2017-2024
Inserm
2022-2023
Ospedale Antonio Cardarelli
2020
Blood Transfusion Centre of Slovenia
2020
Centro Regional de Hemodonación
2011-2018
Universidad de Murcia
2011-2018
Université Paris-Sud
2017
Instituto de Salud Carlos III
2014
Background. The benefit of the combination serum galactomannan (GM) assay and polymerase chain reaction (PCR)–based detection Aspergillus DNA for early diagnosis therapy invasive aspergillosis (IA) in high-risk hematological patients remains unclear.
CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory large B-cell lymphomas. However, some may die causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known about the nonrelapse mortality (NRM) Using French DESCAR-T registry, we analyzed incidence NRM identified risk factors NRM. We report on 957 who received standard-of-care axicabtagene ciloleucel (n = 598) or...
Abstract Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is most frequent CAR T-cell–related adverse event. Transfusion support a surrogate marker severe cytopenias. affects patients’ quality life, presents specific toxicities, and known to affect immunity through so-called transfusion-related immunomodulation that may T-cell efficacy. We analyzed data from 671 patients French DESCAR-T...
There is an increased risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it standard practice to use rabbit anti-thymocyte globulin (rATG) reduce the high NRM risks MMUD alloSCT. As alternative rATG, post-transplantation Cyclophosphamide (PTCy) in increasing clinical use. It currently impossible give general recommendations regarding preference for one method over another since...
Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with severe, treatment-refractory Crohn's disease [CD]. The evidence base AHSCT CD limited, one randomised trial [ASTIC] suggesting benefit. aim of this study was to evaluate safety and efficacy undergoing in Europe, outside the ASTIC trial. We identified 99 European Society Blood Marrow Transplantation [EBMT] registry, who were eligible inclusion. Transplant clinical outcomes obtained 82 from 19...
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25 years and is now validated by national international medical societies early systemic sclerosis (SSc) relapsing-remitting multiple (MS) available as part of routine care in accredited center. HSCT also recommended, with varying levels evidence, an alternative treatment several ADs, when refractory to conventional therapy, including specific cases connective tissue diseases or vasculitis, inflammatory...
Abstract Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles challenged by CAR-T-cells other immunotherapies. We examined the trends outcomes DLBCL patients undergoing auto-/allo-HSCT between 1990 2021 reported to EBMT. Over this period, 41,148 underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 2018. The recent decline...
<title>Abstract</title> Chronic graft versus host disease is a major cause of morbidity after allogeneic haematopoietic cell transplantation. Belumosudil has recently been approved for the treatment cGVHD refractory two lines treatment. However, few data are available to evaluate its efficacy and safety in real life. 68 patients with received belumosudil through compassionate access program France. The median follow-up was 337 days from initiation. Eighty-two percent had severe three organs...
Allogeneic hematopoietic stem cell transplantation remains the best curative option for higher-risk myelodysplastic syndrome. The presence of monosomal karyotype and/or complex abnormalities predicts inferior survival after allo-SCT in MDS patients. Haploidentical has been increasingly used acute leukemia (AL) and similar results as using HLA-matched donors, but data on is sparse. We compared outcomes 266 patients with sibling donor (MSD, n = 79), unrelated (MUD, 139) HLA haploidentical...
Summary The current study was designed to assess the safety and efficacy of bortezomib in combination with fludarabine melphalan as reduced intensity conditioning before allogeneic stem cell transplantation patients high risk multiple myeloma. Sixteen were evaluable. median number previous line treatment 3; all had relapsed following a prior autograft 13 previously received bortezomib. Fifteen them either remained stable or improved disease status at day +100 post‐transplant, including 11...
Definition of therapy-related myeloid neoplasms (TRMN) is only based on clinical history exposure to leukemogenic therapy. No specific molecular classification combining acute leukemia and myelodysplastic syndromes has been proposed. We aimed describe the landscape TRMN at diagnosis, among 77 patients with previous gynecologic breast cancer a dedicated next-generation sequencing panel covering 74 genes. investigated impact clonal hematopoiesis indeterminate potential-associated mutations...
The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, COVID-19 prompted prophylactic use of engineered anti-SARS-CoV-2 monoclonal antibodies. In addition, potential clinical significance T cell responses has been overlooked during first waves pandemic, calling additional in-depth studies. We reported that polarity repertoire...
The combination of carmustine, etoposide, aracytin, and melphalan(BEAM) conditioning regimen in autologous stem-cell transplantation (ASCT) is widely used patients with relapsed/refractory non-Hodgkin lymphoma (NHL) Hodgkin lymphoma. It also an option very-high risk aggressive NHL first complete remission (CR). Recently, a phase Ib-II feasibility study using bendamustine replacing carmustine (BCNU) was reported. We report herein safety efficacy analysis bendamustine-EAM (BeEAM) control BEAM...
Peripheral expansion of cytotoxic T lymphocytes (CTL) derived from the graft in initial stages allogeneic haematopoietic stem cell transplantation (alloHSCT) immune recovery is a well-known physiological event. The description symptomatic large granular lymphocyte leukaemia this setting may generate uncertainty, mostly those cases which CTL (CTLe) persists beyond early period. We aimed to assess nature CTLe during post-alloHSCT period 154 adult patients with long-term surveillance. studied...